EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H1 2015

  • ID: 3259620
  • Report
  • April 2015
  • 81 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • 4SC AG
  • Biofrontera AG
  • Biogenomics Limited
  • Genextra S.p.a.
  • MediGene AG
  • Novartis AG
  • MORE
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H1 2015

Summary

This, ‘Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H1 2015’, provides an overview of the Basal Cell Carcinoma (Basal Cell Epithelioma)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma) and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Basal Cell Carcinoma (Basal Cell Epithelioma)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Basal Cell Carcinoma (Basal Cell Epithelioma) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Basal Cell Carcinoma (Basal Cell Epithelioma) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Basal Cell Carcinoma (Basal Cell Epithelioma) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Basal Cell Carcinoma (Basal Cell Epithelioma)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Basal Cell Carcinoma (Basal Cell Epithelioma) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • 4SC AG
  • Biofrontera AG
  • Biogenomics Limited
  • Genextra S.p.a.
  • MediGene AG
  • Novartis AG
  • MORE
List of Tables
List of Figures
Introduction
REPORT COVERAGE
Basal Cell Carcinoma (Basal Cell Epithelioma) Overview
Therapeutics Development
Pipeline Products for Basal Cell Carcinoma (Basal Cell Epithelioma) - Overview
Pipeline Products for Basal Cell Carcinoma (Basal Cell Epithelioma) - Comparative Analysis
Basal Cell Carcinoma (Basal Cell Epithelioma) - Therapeutics under Development by Companies
Basal Cell Carcinoma (Basal Cell Epithelioma) - Therapeutics under Investigation by Universities/Institutes
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Basal Cell Carcinoma (Basal Cell Epithelioma) - Products under Development by Companies
Basal Cell Carcinoma (Basal Cell Epithelioma) - Products under Investigation by Universities/Institutes
Basal Cell Carcinoma (Basal Cell Epithelioma) - Companies Involved in Therapeutics Development
4SC AG
Biofrontera AG
Biogenomics Limited
Biosceptre International Limited
Bristol-Myers Squibb Company
Genextra S.p.a.
MediGene AG
Novartis AG
Oncovir, Inc.
Redx Pharma Ltd
Transgene SA
Basal Cell Carcinoma (Basal Cell Epithelioma) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
aminolevulinic acid hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BIL-010t - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BMS-833923 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CIGB-128 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CS-S/BCC-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CS-TATI-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DAC-060 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
erismodegib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
interferon alfa-2b (recombinant) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LEQ-506 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oshadi D + Oshadi R - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Poly-ICLC - Drug Profile
Product Description
Mechanism of Action
R&D Progress
sinecatechins - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit Smoothened Receptor for Basal Cell Carcinoma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit Casein Kinase 1 for Cancer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TG-1042 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Basal Cell Carcinoma (Basal Cell Epithelioma) - Recent Pipeline Updates
Basal Cell Carcinoma (Basal Cell Epithelioma) - Dormant Projects
Basal Cell Carcinoma (Basal Cell Epithelioma) - Discontinued Products
Basal Cell Carcinoma (Basal Cell Epithelioma) - Product Development Milestones
Featured News & Press Releases
Mar 02, 2015: Basal Cell Carcinoma Drug Encourages Both Cancer Regression and Loss of Taste in Patients
Sep 17, 2014: Novartis presents oncology research advances with new data on sonidegib at ESMO 2014
Jul 22, 2014: Biosceptre Announces Positive Phase I Results for BIL-010t to Treat Basal Cell Carcinoma
Jun 01, 2014: Pivotal data for Novartis' investigational compound LDE225 show marked tumor responses in advanced basal cell carcinoma
May 23, 2014: Curis Announces Abstracts for Its Partnered Programs, Erivedge to be Presented at the 2014 ASCO Annual Meeting
Feb 19, 2014: Novartis investigational compound LDE225 met primary endpoint in pivotal trial for patients with advanced basal cell carcinoma
Jul 15, 2013: Roche’s Erivedge receives conditional EU approval for treatment of advanced basal cell carcinoma
Jun 11, 2013: Roche's Erivedge Gets Swiss Approval For Treatment Of Basal Cell Carcinoma
May 16, 2013: Curis Announces Presentation Of Erivedge Clinical Results At ASCO Annual Meeting
May 10, 2013: Curis Obtains Australian Approval For Erivedge For Treatment Of Adult Patients With Metastatic Basal Cell Carcinoma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma), H1 2015
Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Investigation by Universities/Institutes, H1 2015
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by 4SC AG, H1 2015
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Biofrontera AG, H1 2015
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Biogenomics Limited, H1 2015
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Biosceptre International Limited, H1 2015
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Bristol-Myers Squibb Company, H1 2015
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Genextra S.p.a., H1 2015
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by MediGene AG, H1 2015
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Novartis AG, H1 2015
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Oncovir, Inc., H1 2015
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Redx Pharma Ltd, H1 2015
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Transgene SA, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Basal Cell Carcinoma (Basal Cell Epithelioma) Therapeutics - Recent Pipeline Updates, H1 2015
Basal Cell Carcinoma (Basal Cell Epithelioma) - Dormant Projects, H1 2015
Basal Cell Carcinoma (Basal Cell Epithelioma) - Discontinued Products, H1 2015

List of Figures
Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma), H1 2015
Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015
Note: Product cover images may vary from those shown
3 of 4
4SC AG
Biofrontera AG
Biogenomics Limited
Biosceptre International Limited
Bristol-Myers Squibb Company
Genextra S.p.a.
MediGene AG
Novartis AG
Oncovir, Inc.
Redx Pharma Ltd
Transgene SA
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll